BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
68.88
+5.07 (7.95%)
At close: Aug 10, 2026, 4:00 PM EDT
68.55
-0.33 (-0.48%)
Pre-market: Aug 11, 2026, 8:04 AM EDT
BioMarin Pharmaceutical Market Cap
BioMarin Pharmaceutical has a market cap or net worth of $13.33 billion as of August 11, 2026. Its market cap has increased by 21.12% in one year.
Market Cap
13.33B
Enterprise Value
16.66B
1-Year Change
21.12%
Ranking
Category
Stock Price
$68.88
ChartMarket Cap Chart
Since July 26, 1999, BioMarin Pharmaceutical's market cap has increased from $443.40M to $13.33B, an increase of 2,907.07%. That is a compound annual growth rate of 13.40%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 10, 2026 | 13.33B | 16.78% |
| Dec 31, 2025 | 11.42B | -8.86% |
| Dec 31, 2024 | 12.53B | -31.03% |
| Dec 29, 2023 | 18.16B | -5.57% |
| Dec 30, 2022 | 19.23B | 18.58% |
| Dec 31, 2021 | 16.22B | 1.90% |
| Dec 31, 2020 | 15.92B | 4.81% |
| Dec 31, 2019 | 15.19B | 0.17% |
| Dec 31, 2018 | 15.16B | -3.18% |
| Dec 29, 2017 | 15.66B | 9.92% |
| Dec 30, 2016 | 14.25B | -15.66% |
| Dec 31, 2015 | 16.89B | 26.72% |
| Dec 31, 2014 | 13.33B | 33.25% |
| Dec 31, 2013 | 10.00B | 64.58% |
| Dec 31, 2012 | 6.08B | 54.81% |
| Dec 30, 2011 | 3.93B | 42.26% |
| Dec 31, 2010 | 2.76B | 45.68% |
| Dec 31, 2009 | 1.89B | 6.63% |
| Dec 31, 2008 | 1.78B | -48.15% |
| Dec 31, 2007 | 3.43B | 128.90% |
| Dec 29, 2006 | 1.50B | 87.98% |
| Dec 30, 2005 | 796.50M | 93.28% |
| Dec 31, 2004 | 412.10M | -16.92% |
| Dec 31, 2003 | 496.00M | 31.08% |
| Dec 31, 2002 | 378.40M | -36.33% |
View and export this data all the way back to 1999. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| BridgeBio Pharma | 16.55B |
| Exelixis | 13.12B |
| Arrowhead Pharmaceuticals | 12.38B |
| Corcept Therapeutics | 12.35B |
| Madrigal Pharmaceuticals | 11.91B |
| Summit Therapeutics | 11.86B |
| Halozyme Therapeutics | 11.65B |
| Axsome Therapeutics | 11.37B |